The Target Pediatric AML (TpAML) project is endorsed by the Children’s Oncology Group (COG) leadership and Myeloid Disease Committee. COG directs all research efforts in close partnership with Fred Hutch (Seattle), BCCA’s Cancer Genome Sciences Centre (Vancouver), and FoundationOne Heme (Boston).
If your organization has specific expertise in cancer genomics, big data analysis, therapeutic target identification, drug repurposing, targeted drug development, or patient-centered drug matching/screening (and you are interested in partnering with TpAML), contact us.
The Target Pediatric AML project is lead, from a research perspective, by the Children’s Oncology Group’s Myeloid Disease (AML) Committee:
Dr. Soheil Meshinchi, COG Myeloid Disease Committee Biology Chair
British Columbia Cancer Agency’s (BCCA’s) Genome Sciences Centre – Deep, omic sequencing & data analysis
National Cancer Institute (NCI) – Target AML, data storage
FoundationOne Heme – Clinical genomic testing